Interregulation between Fragile X Mental Retardation Protein and Methyl CpG Binding Protein 2 in the Mouse Posterior Cerebral Cortex

Jason Arsenault¹,³,⁶,* Alexander W. M. Hooper¹, Shervin Gholizadeh¹, Tian Kong³,⁶, Laura K. Pacey¹, Enea Koxhioni¹, Yosuke Niibori¹, James H. Eubanks²,³,⁴, Lu-Yang Wang³,⁶, and David R. Hampson¹,⁵

1. Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, M5S 3M2.
2. Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
3. Department of Physiology, University of Toronto, Toronto, ON, Canada.
4. Department of Surgery (Neurosurgery), University of Toronto, Toronto, ON, Canada.
5. Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, M5S 1A8.
6. Program in Neurosciences and Mental Health, Hospital for Sick Children Research Institute, Toronto, ON, Canada, M5G 0A4.

*To whom correspondence should be addressed: jason.arsenault@sickkids.ca. NMH, Hospital for Sick Children Research Institute, Toronto, ON, Canada, M5G 0A4. tel.: (416) 813-1500. Fax: 416-813-7717.

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Abstract

Several X-linked neurodevelopmental disorders including Rett Syndrome, induced by mutations in the MECP2 gene, and Fragile X Syndrome (FXS), caused by mutations in the FMR1 gene, share autism-related features. The mRNA coding for Methyl CpG binding protein 2 (MeCP2) has previously been identified as a substrate for the mRNA-binding protein Fragile X Mental Retardation Protein (FMRP), which is silenced in FXS. Here, we report a homeostatic relationship between these two key regulators of gene expression in mouse models of FXS (Fmr1 KO) and Rett syndrome (MeCP2 KO). We found that the level of MeCP2 protein in the cerebral cortex was elevated in Fmr1 KO mice, whereas MeCP2 KO mice displayed reduced levels of FMRP, implicating interplay between the activities of MeCP2 and FMRP. Indeed, knockdown of MeCP2 with short hairpin RNAs led to a reduction of FMRP in mouse Neuro2A and in human HEK-293 cells, suggesting a reciprocal coupling in the expression level of these two regulatory proteins. Intra-cerebroventricular injection of an adeno-associated viral vector coding for FMRP (AAV-FMRP) led to a concomitant reduction in MeCP2 expression in vivo, and partially corrected locomotor hyperactivity. Additionally, the level of MeCP2 in the posterior cortex correlated with the severity of the hyperactive phenotype in Fmr1 KO mice. These results demonstrate that MeCP2 and FMRP operate within a previously undefined homeostatic relationship. Our findings also suggest that MeCP2 overexpression in Fmr1 KO mouse posterior cerebral cortex may contribute to the fragile X locomotor hyperactivity phenotype.
**Introduction**

Several X-linked neurodevelopmental disorders including Fragile X Syndrome (FXS) and Rett Syndrome display shared symptoms associated with autism spectrum disorders (ASD) and are characterized by impairments in social interaction and communication, and repetitive stereotyped patterns of behavior (1, 2). The Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V) classifies FXS as an intellectual disability disorder on the autism spectrum. The disorder is caused by a CGG expansion of the 5' region of the *FMR1* gene causing impairment of FMRP protein expression required for normal neurological function. Approximately 30-40% of FXS patients fit the full diagnostic criteria for ASD, while more than 75% display at least some autistic characteristics (1, 3, 4). Rett Syndrome, caused by *de novo* mutations that impair MeCP2 protein function or expression (5, 6), was previously classified as a pervasive developmental disorder, but was not included in the ASD classification in the DSM-V (7). Like FXS, this disorder displays overlapping clinical features associated with ASD including intellectual and locomotor deficits.

FMRP functions as an mRNA-binding protein and acts as a wide-spectrum translational modulator via its ability, among others, to stall ribosomal translation (8-10). FMRP has also been implicated in microRNA (miRNA) processing, maturation and nuclear export, and participates in RNA-Induced Silencing Complex (RISC)-mediated mRNA processing (11-13). FMRP also plays a role in (a) mRNA stability (14, 15), (b) regulation of intracellular trafficking, (c) as an allosteric modulator of K⁺ channel activity through protein-protein interactions (16-18), and (d) contributes to intracellular phase separation of neuronal granules (10, 19). The absence of FMRP's pleiotropic activity in FXS results in aberrant up and downregulation of several proteins required for cellular differentiation, proper synaptic function, and neuronal plasticity.
In contrast to FMRP-mediated translational modulation, MeCP2, which binds methylated CpG DNA sequences, both represses and activates gene transcription (20, 21). Additional studies suggest that MeCP2 also participates in RNA splicing (22, 23) as well as miRNA regulation (24). MeCP2 is post-transcriptionally regulated in a spatiotemporal manner during brain development (25). The necessity for precise control of MeCP2 and FMRP expression levels is highlighted by case studies that reveal the neurodevelopmental consequences of FMR1 (26-29) and MeCP2 gene duplications (30). MeCP2 duplication syndrome is manifested by profound neurodevelopmental abnormalities and shows similarities to FMRP gene duplication where patients display severe intellectual disability, anxiety, impaired language and motor skills, hypotonia, and stereotyped behaviors (30-33).

Here, we investigated the interrelationship of these two key proteins in the context of wild-type (WT), Fmr1 KO and MeCP2 KO mice. In cerebral cortical tissue, MeCP2 protein levels were upregulated in Fmr1 KO mice while FMRP was downregulated in MeCP2 KO mice. The expression of MeCP2 and FMRP was inversely regulated on a cell autonomous level in wild-type (WT) and in Fmr1 KO mice transduced with an adeno-associated viral (AAV) vector coding for FMRP. Notably, MeCP2 protein overexpression significantly correlated with the severity of locomotor hyperactivity, suggesting a link to FXS symptomology. Our results demonstrate that brain levels of FMRP and MeCP2 are inter-linked with each other, suggesting that elevated MeCP2 may contribute to the FXS phenotype, and conversely, that reduced FMRP may contribute to the Rett Syndrome phenotype.

Results

Biochemical and Cytological Characterization of MeCP2 in WT and Fmr1 KO Mice
To evaluate the cellular relationship between FMRP and MeCP2, we used confocal microscopy to determine whether the two proteins are co-expressed within the same cells. In the motor cortex of WT mouse brain both FMRP and MeCP2 were expressed within the same cells, albeit primarily in different subcellular compartments (FMRP predominantly in the cytosol; MeCP2 in the nucleus). As expected, both proteins were co-expressed primarily within cells that also expressed the neuron specific marker NeuN, confirming the neuronal identity of the cells that display elevated MeCP2 or elevated FMRP (Suppl. Fig. 1A and B). Relative NeuN intensity directly correlated with both FMRP and MeCP2 immunoreactivity on the individual cell level (p<0.01). Neuronal co-expression of FMRP and MeCP2 can also be seen in the cerebral cortex (Fig. 1A), striatum (Fig. 1B), and hippocampus (Fig. 1C), as well the deep cerebellar nuclei and the cerebellar cortex (Fig. 1D-F). Thus, previous evidence that MeCP2 mRNA could be a substrate of FMRP (8, 34), together with the observation here that both proteins are largely present within the same cells, suggests that they are physically co-expressed to potentially allow interregulation in a cell autonomous fashion.

Further investigation was carried out to access the ability of FMRP to bind MeCP2 mRNA transcript variants. Immuno-precipitations of cortical homogenates from WT mice using an anti-FMRP antibody were performed; PSD-95 mRNA, a well-established substrate of FMRP, was used as a positive control (Fig. 1G). MeCP2 has two major isoforms; MeCP2 transcript isoform 1 is expressed throughout the brain, while isoform 2 is less abundant with restricted expression in the CNS and differs from isoform 1 only in its N-terminus (35, 36). Amplification of MeCP2 transcripts 1 (Fig. 1H) and 2 (Fig. 1I) specific mRNAs from the anti-FMRP immunoprecipitate indicated the presence of both variants. Samples containing the non-specific IgG immunoprecipitate did not produce detectable MeCP2 or PSD95 amplicon, further
confirming the specific nature of the FMRP-MeCP2 mRNA interaction. Because of the amplificating nature of the PCR reaction, the primers used were sufficient for qualitative identification of the two MeCP2 isoforms, but the transcripts could not be compared quantitatively by Q-PCR as they displayed variations in the annealing temperature; thus, only the presence or absence of each mRNA could be confirmed using these probes. Nevertheless, these results support that FMRP is able to bind both MeCP2 transcript variants. Thus, we were also able to detect the presence of MeCP2 mRNA within the specific FMRP immunoprecipitate as was previously observed in a HITS-CLIP assay of whole brain lysate in 2011 (8). However, quantitative reverse transcriptase PCR using primers coding for combined MeCP2 transcript variants 1 and 2, showed no differences in total MeCP2 mRNA expression in WT compared to Fmr1 KO mice forebrains (Fig. 2A), indicating that FMRP itself, or the homeostatic result of the absence of FMRP, does not alter the transcription rate of MeCP2 DNA into mRNA by a noticeable degree. To examine MeCP2 under conditions of variable FMRP expression, MeCP2 protein quantification was carried out on adult (2-month old) wild-type and Fmr1 KO mice that were injected on postnatal day (PND) 0 or 1 with either a control vector carrying no transgene (AAV-empty vector; AAV-EV), or an AAV vector carrying the FMRP transgene (AAV-FMRP). Three test groups of mice were studied: WT mice injected with AAV-EV, Fmr1 KO mice injected with AAV-EV, and Fmr1 KO mice injected with AAV-FMRP. Immunoblot analysis demonstrated that, compared to WT controls injected with AAV-EV, MeCP2 protein was overexpressed in the posterior cerebral cortex of the adult Fmr1 KO mice injected with the same control vector (Fig. 2B). Importantly, MeCP2 overexpression in adult Fmr1 KO mice was normalized after treatment with AAV-FMRP (KO + AAV-FMRP group), as would be expected for an FMRP substrate with a lack of translational repression. Densitometric quantification (Fig.
revealed that the elevated MeCP2 protein expression observed in *Fmr1* KO mice injected with AAV-EV (132 ± 8%, p < 0.05; N = 12) was significantly reduced in the group of *Fmr1* KO mice injected with AAV-FMRP (89 ± 11%, p < 0.01; N = 14). These results demonstrated that MeCP2 overexpression in the *Fmr1* KO mice is not caused by an elevation in MeCP2 gene transcription, but rather, is due to a deficiency in post-transcriptional regulation. Together, these findings indicate that the absence of FMRP leads to upregulation of MeCP2 protein, and that this can be corrected in the mouse brain *in vivo* by the introduction of exogenous AAV-FMRP.

**Single Cell Analyses of MeCP2 and FMRP Expression in the Sensorimotor Cortex**

To assess the effects of intracellular FMRP levels on MeCP2 protein expression, we exploited the cellular variability of transgene uptake and expression previously reported in *Fmr1* KO mice transduced with AAV-FMRP (37). Because a synapsin promoter was used to drive AAV-FMRP neuron-specific transgene expression (34, 37), we chose to quantify the MeCP2 expression levels in the nucleus of individual neurons relative to the level of FMRP expressed in the cytosol of those same cells. Eight weeks following a PND 0-1 bilateral intra-cerebroventricular (i.c.v.) injection of AAV-FMRP, immunocytochemistry was performed on coronal sections of fixed brain tissue. Endogenous MeCP2 expression was present in virtually all cells of the sensorimotor cortex and consistently co-localized with DAPI nuclear staining. As seen in WT neurons (e.g. see Fig. 1A), the AAV-FMRP transduced neurons displayed expected intracellular distribution patterns of the proteins with nuclear localization of MeCP2 and cytosolic localization of FMRP. Three serial coronal sections of the sensorimotor cortex obtained from four KO + AAV-FMRP mice were used in subsequent analyses. MeCP2 immunoreactivity was then analyzed as a function of FMRP immunoreactive intensity within the same cells. An
inverse relationship ($R = -0.14$, $p < 0.001$; $N = 2358$ cells; Fig. 2D) between the single cell immunoreactivity of MeCP2 and FMRP (e.g. Fig. 2E) was observed using unbiased MATLAB quantification. Cells labeled with FMRP and NeuN, as well as MeCP2 and NeuN, displayed a direct correlation where high-FMRP coincided with high-NeuN staining, which confirmed their neuronal identity (Suppl. Fig. 1A and B; left panels). When the cells were co-labeled with the astrocyte marker S100β and FMRP, or S100β and MeCP2, an inverse relationship was observed (using the MATLAB quantification, Suppl. Fig. 1A and B; right panels). This "L-shaped" scattered distribution indicated that in the motor cortex high-FMRP or high-MeCP2 cells rarely co-localize with cells expressing a high level of S100β (Suppl. Fig. 1B). More importantly given that an independent analysis from the scatter plots of the MeCP2 and FMRP immunoreactivity in the posterior cortex also adopts an L-shape (Fig. 2D), and knowing that both high-MeCP2 and high-FMRP cells are predominantly neuronal, we can conclude that the neurons express either high-FMRP or high-MeCP2, but rarely both simultaneously (1%). Flow cytometry of the papain-digested sensorimotor cortex from 2-month old C57BL/6 WT mice confirmed the reliability of the cell counts (Suppl. Fig. 2) whereby high-FMRP and high-MeCP2 expressing cells also adopted an L-shaped scatter distribution. This relationship implies that as FMRP levels increase, either from endogenous expression or transgenic delivery, MeCP2 protein expression is concomitantly, and proportionally, downregulated.

Characterization of FMRP in MeCP2 KO Mice

The observation that FMRP expression in Fmr1 KO mice transduced with AAV-FMRP induced a normalization of MeCP2 levels (Fig. 2B-D) raises the question as to the status of FMRP levels in the absence of MeCP2. Therefore, we performed densitometric quantification of FMRP in the
cerebral cortex and cerebellum of adult MeCP2 KO mice using western blotting. As expected, MeCP2 protein was highly expressed in the cerebral cortex and cerebellum of WT mice, and was not detected in strain-matched MeCP2 KO mouse samples (Fig. 3A), thereby confirming the specificity of the MeCP2 antibody used for western blotting. FMRP expression was also quantified and compared in the cerebellum (Fig. 3B and D) and cerebral cortex (Fig. 3C and E) of WT and MeCP2 KO mice. FMRP expression in the MeCP2 KO cerebellum was not significantly different from WT, whereas a significant reduction of FMRP was observed in the cerebral cortex of MeCP2 KO mice (78 ± 5% of WT expression, p < 0.01, N = 9; Fig. 3E). Therefore, in contrast to the upregulation of MeCP2 observed in the Fmr1 KO mouse brain, the absence of MeCP2 in the MeCP2 KO mouse cortex showed significantly reduced FMRP expression.

Manipulation of MeCP2 expression in cell lines
To ascertain if anti-sense mediated downregulation of MeCP2 could directly influence FMRP expression, we assayed five different shRNA plasmids from Sigma's Mission shRNA library. All five plasmids targeting human MeCP2 showed significant downregulation of MeCP2 protein expression from plated mouse N2A cells, validating their efficacy in vitro (Fig. 4A, B). Marked downregulation was observed by western immunoblotting and quantification, normalized to GAPDH, showed a significant 70-85% reduction in MeCP2 protein levels in N2A cells with all shRNAs examined (Fig. 4B). Interestingly, FMRP protein levels were also concomitantly downregulated (Fig. 4C). Normalized protein quantification showed a marked 35-45% reduction in FMRP protein expression for each tested MeCP2 specific shRNA, with a significant reduction observed for the 579, 1266, and 1266s21 shRNA plasmids (p < 0.05; Fig. 4C). Taken together
with the MeCP2 KO mice quantification data, this observation confirms that reducing MeCP2 protein levels, whether through embryonic mutations or *in vitro* transfection of immortalized mouse neuroblastomas, leads to a concomitant downregulation of FMRP.

To further probe this relationship, we also tested a pooled AAV2/9 siRNA virus that specifically targeted human MeCP2 (hMeCP2) mRNAs and included a GFP reporter within the same expression cassette. To this end, we used the human embryonic kidney cell line, HEK-293. Using a commercially available anti-hMeCP2 AAV2/9, we assayed three different viral doses (2x10^6, 2x10^7, and 6x10^7 GC/ml) by adding it directly to the culture media of HEK-293 cells. In cells collected 42h post-transfection, western immunoblotting analysis revealed an increase in the positive reporter GFP, downregulation of MeCP2, and a concomitant downregulation of FMRP (Fig. 5A) in a dose dependant manner (Fig. 5B). MeCP2 protein quantification showed a significant downregulation in the highest viral dose condition (Fig. 5B and C; p < 0.05). As observed in mouse N2A cells, FMRP levels were also decreased relative to GAPDH in this human derived cell line, but in HEK-293 cells the FMRP downregulation appeared to be as robust, if not more so, than the specific MeCP2 knockdown itself (Fig. 5B and D). This observation confirms that MeCP2 downregulation also led to FMRP downregulation in human cells, thereby demonstrating that the MeCP2 effects on FMRP levels are not restricted to mouse translational/transcriptional regulatory mechanisms.

**Correlation between FMRP, MeCP2, and Motor Activity**

Locomotor hyperactivity is a key hallmark of human FXS and *Fmr1* KO mice (34, 37, 38). Therefore, we performed open field locomotor activity measurements in conjunction with subsequent quantification of protein expression. Adult *Fmr1* KO mice injected with AAV-EV
displayed a significant elevation in motor activity compared with WT mice injected with AAV-EV (as indicated by the total distance travelled within 10 minutes; Fig. 6A and 6B; p < 0.05, N = 40). Motor hyperactivity was partially normalized in the KO + AAV-FMRP treatment group compared to the KO + AAV-EV group, resulting in the AAV-FMRP treatment group not being significantly different from the WT AAV-EV group (*i.e.* treatment with AAV-FMRP reduced motor hyperactivity in the KO mice; Figure 6B). In parallel, *i.c.v.* injection of AAV-FMRP in the *Fmr1* KO mice increased the FMRP expression in the posterior cerebral cortex to 69±13% (n=14) of WT levels, similar to previously reported (34).

Given that re-introduction of FMRP via AAV-FMRP may lead to the expression of variable levels of cortical FMRP transgene expression from mouse-to-mouse, we endeavored to explore potential correlations between expression level and motor activity. No significant linear correlation was observed between the levels of FMRP and total distance travelled (Fig 6C). However, given the observed inverse relationship between FMRP and MeCP2 expression, we also analyzed the relationship between locomotion and MeCP2 levels in individual mice (Fig. 6D). Remarkably, when the total distance travelled was analyzed as a function of MeCP2 expression in the posterior cerebral cortex of individual mice (WT + EV, *Fmr1* KO + EV, *Fmr1* KO + AAV-FMRP; Fig. 6D), we found a significant correlation between these two parameters (Fig. 6D, R=0.42, p < 0.01; N = 40). To further substantiate this finding, we examined previously unpublished motor activity and MeCP2 protein expression results obtained from a separate group of injected mice from our previous study (37). Wild-type controls and *Fmr1* KO mice both injected with AAV-FMRP were analyzed for total distance travel as a function of MeCP2 expression levels; this analysis also showed a direct correlation between motor activity and MeCP2 expression (Fig. 6E, R = 0.86, p < 0.001; N = 11). Finally, we note that the converse
of the results described here were reported by Wither et al., 2013 (39) who studied MeCP2 haplo-insufficient mice (hypoactive) and reported that MeCP2 protein expression correlated directly with locomotor activity.

To determine whether MeCP2 overexpression might be induced from the innate increased locomotor activity in *Fmr1* KO mice, naive WT and *Fmr1* KO mice were maintained under acute sedation with ketamine and xylazine for 10 hours, after which the expression of MeCP2 was quantified in the cortex. Acute suppression of locomotor activity did not significantly alter MeCP2 expression compared to non-sedated littermates (Suppl. Fig. 3). This observation suggests that the MeCP2 over-expression in *Fmr1* KO mice was not driven by the elevated locomotor activity *per se*, but rather MeCP2 over-expression is directly related to the absence of FMRP in neurons.

**Discussion**

In this study, we sought to investigate the possibility of interregulation, or cross-talk between FMRP and MeCP2. Our findings reveal a previously undocumented homeostatic relationship between MeCP2 and FMRP expression. The observation that both proteins are widely co-expressed within the same cells indicated that an interrelationship between the two could occur on a cell autonomous level. We determined that MeCP2 protein expression was upregulated in the *Fmr1* KO mouse, whereas FMRP expression was reduced in *MeCP2* KO mouse cortex.

Since pathologies emerge when the expression of MeCP2 and FMRP are either hypo- or hyper-expressed, the discovery that *Fmr1* KO mice display overexpression of MeCP2 while *MeCP2* KO mice display reduced FMRP, implies potential cross-contributions to the phenotypes of these two neurodevelopmental disorders.
Motor hyperactivity is a salient characteristic of FXS. This study is the first to link cortical MeCP2 levels to locomotor activity in Fmr1 KO mice. This finding was revealed by plotting the relationship between motor activity and cortical MeCP2 levels in individual mice injected with AAV-FMRP; MeCP2 expression levels in these mice in the posterior cerebral cortex correlated directly with locomotor activity. We also investigated whether MeCP2 expression in the posterior cortex correlated with other behaviors in the same cohort of mice, but we did not observe additional significant correlations outside of locomotor activity. A link between MeCP2 in the cortex and motor activity was also indicated in a previous study conducted in MeCP2 haplo-insufficient female mice, where locomotor hypoactivity and low levels of MeCP2 were correlated (39), and in another study where hypoactivity was rescued following the re-introduction of transgenic MeCP2 (40). In contrast to MeCP2, we did not observe a correlation between FMRP expression in the posterior cortex and motor activity. However, in our earlier work we demonstrated that FMRP expression levels in the striatum of AAV-FMRP-treated Fmr1 KO mice correlated with the time and number of entries into the open arm of the elevated plus maze test of non-social anxiety (34).

Although the underlying biochemical pathways mediating interregulation of FMRP and MeCP2 were not the focus of this study, several mechanistic processes can be postulated. For instance, a number of MeCP2 binding elements are present upstream of the FMR1 gene (41-43). Moreover, the loss of FMRP-associated non-coding RNA regulation in FXS and Fmr1 KO mice, including long non-coding RNAs and micro-RNAs (12, 44, 45), could potentially alter MeCP2 expression.

Previous work from our laboratory demonstrated that mild to moderate AAV-mediated overexpression of FMRP (less than 1.5-fold over WT) did not lead to severe adverse effects in
WT or Fmr1 KO mice (34). However, very high level FMRP overexpression in Fmr1 KO mice induced by AAV-FMRP administration (>2.5 fold over WT) caused aberrant behaviors (e.g. abnormal startle responses), and transgenic mice overexpressing FMRP several-fold over WT displayed increased anxiety and a reversal of the motor activity rescue (46). In comparison with FMRP where abnormal behaviors were only seen after very high overexpression, mild to modest upregulation of MeCP2 in transgenic mice has been shown to induce seizures and motor hypoactivity (40, 47, 48). The severe consequences of MECP2 overexpression are further illustrated by case studies where patients with chromosomal duplications overlapping the MECP2 gene were found to induce profound intellectual disability, speech deficits, and impaired immune function (31, 33). Our findings raise an intriguing question: could the suppression of brain MeCP2 expression be therapeutically beneficial in FXS? The higher demographic prevalence of autism in males and the finding that MeCP2 and FMRP display interregulation suggests that the conserved placement of FMRP and MeCP2 on the X chromosome in mammals might not be a stochastic happenstance of evolution, but rather, a conserved homeostatic mechanism. A balance between the transcriptional output of MeCP2 and the translational modulation by FMRP, as well as other X-linked transcriptional and translational modulators, may represent an important regulatory mechanism implicated not only in maintaining normal neurological function, but possibly also in the sexual dimorphism of some behaviors (49, 50).

Materials and methods

Animals

Wild-type and Fmr1 KO mice, both on the C57BL/6 background, were used in this study as described elsewhere (34). MeCP2 KO mice were obtained from Jackson Laboratories.
(B6.129P2(C)-Mecp2<sup>tm1.Bird</sup> (51). All protocols were approved by the University of Toronto Animal Care Committee and are in accordance with the Canadian Council on Animal Care guidelines.

**AAV Vectors and AAV Vector Injections**

Single-stranded AAV2/9 vector containing the human synapsin-1 (Syn) promoter and the mouse coding region of FMRP (isoform 1) was supplied by the University of Pennsylvania Vector Core Facility (Philadelphia, PA). This AAV2/9 vector (AAV-FMRP), which has been described in our previous work (34, 37), was used at a titer of $1 \times 10^{13}$ genomes/ml in sterile phosphate-buffered saline (PBS; 140 mM NaCl, 2.7 mM KCl, 10 mM H<sub>2</sub>PO<sub>4</sub>, 2 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) and stored at -80°C. Another single stranded AAV vector of the same serotype containing the cytomegalovirus promoter but without the FMRP transgene (AAV-empty vector; AAV-EV), was used as a control as previously described (34) and was also prepared at the University of Pennsylvania Vector Core Facility.

A single bilateral i.c.v. injection of AAV-EV or AAV-FMRP was administered to WT and Fmr1 KO mice on postnatal day (PND) 0 or 1, as previously described (37, 52). Wild-type and Fmr1 KO mice injected with the AAV-Null vector served as control groups or as otherwise indicated.

**Qualitative and Quantitative Reverse Transcriptase Polymerase Chain Reaction of Forebrain and Cortical mRNA**

Immunoprecipitation followed by quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed as described previously (34) using a modification of the method...
described by Pacey et al. (53). The primers, specifically recognizing MeCP2 transcript variants 1 and 2 as well as the primers specific for GAPDH, used for quantitative PCR were described previously (34). The housekeeping gene GAPDH mRNA was used as a normalizing control. The cDNA was diluted 1:25 and quantitative RT-PCR was performed using an ABI Prism 7900 HT (Applied Biosystems) using the Sybr Green detection system (53). Relative mRNA levels were calculated using the relative threshold cycle method (53). Results are shown as mean relative mRNA level (arbitrary units) ± SEM. Data was analyzed using the unpaired student t-test.

**Cell Culture and MeCP2 shRNA assay**

N2A and HEK-293 cells were grown and processed as previously reported for N2A cells (54). Briefly, cells were grown in a 37°C incubator with 5% CO₂. Cells were grown in high glucose DMEM (Gibco) supplemented with 5% Fetal Calf Serum (Gibco) and 1% Penicillin/Streptomycin (Thermo Fisher) and passaged when confluence reached over 90%. For downregulation assays, cells were seeded at 50 000 cells/well in uncoated 12 well plates (1ml). For transfection, 1.2ug of shRNA plasmids (Sigma; Mission shRNA) were added per well 24h after plating and transfected according to manufacturer’s protocol. The shRNA used in this study were (Clone ID): NM_010788.3-1266s21c1 (abbr. 1266s21); NM_010788.3-830s21c1 (830); NM_010788.3-579s21c1 (579); NM_010788.1-531s1c1 (531); and NM_010788.1-1266s1c1 (1266). For viral transduction, a 10⁹ GC/ml concentration of the AAV2/9-siRNA(MeCP2)-GFP, purchased from ABM Good (iAAV04936009), was added directly to the plated cells. 42 h after transfection or viral transduction, the cells were lysed with homogenization buffer (50mM Tris, 1% SDS, pH 7.4) supplemented with protease cocktail inhibitor (Roche). Approximately 2ug of
protein per condition was resolved on SDS-PAGE as described below. All cell measurements were averaged from three replicates.

**Immunocytochemistry and Confocal Microscopy**

At 65 ± 2 days post injection, the AAV-FMRP and AAV-EV injected mice were anesthetized using a Ketamine-Xylazine solution then transcardially perfused with PBS, followed by 4% paraformaldehyde in PBS (pH 7.4). Serial coronal sections were cut at a thickness of 25µm using a cryostat (Leica Microsystems, Wetzlar, Germany) as previously described (37, 55). Free-floating sections were washed with PBS and antigen retrieval was performed as described elsewhere (56). Monoclonal mouse anti-FMRP 5c2 (57) was used along with monoclonal rabbit anti-MeCP2 D4F3 (Cell Signaling, Beverly, USA) at a 1:1000 dilution. To confirm the neuronal lineage of the cells, anti-NeuN (MAB377 from Millipore and ab177487 from Abcam) and anti-S100β (ab868 from Abcam and S2532 from Sigma) were used at 1:1000 dilutions to label neurons and astrocytes, respectively. The sections were labeled with goat anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 594 (1:4000; Jackson Immunoresearch Laboratories, West Grove, USA). DAPI (Sigma-Aldrich) was used to label nuclei. Cell populations quantification was implemented in MATLAB version R2017a (9.2.0) and the code was included in the supplementary information. Only cells fully within this focal plane were quantified. Linear regression was performed using Graphpad Prism 5 to calculate the MeCP2/FMRP correlation parameters.

**Quantitative Western Blotting**
Samples of the cerebellum and cortex were collected and stored at -80°C. The caudal segment of the cerebral cortex which encompasses the retrosplenial area, the anterior cingulate area, the visual area, and the posterior somatomotor area — herein referred to as posterior cerebral cortex for brevity, was also harvested and stored at -80°C as previously described (34). Mouse brain anatomical regions and nomenclature were obtained from the Allen Mouse Brain Reference Atlas (58). Protein concentration was determined using the BCA assay. To properly quantify bands, 10ug of protein were loaded per lane. After SDS-polyacrylamide gel electrophoresis, the proteins were transferred onto PVDF membranes, blocked with a 5% milk (BioShop, Burlington, Canada) solution in PBS, and incubated overnight with the primary antibodies listed above at 1:1000 dilutions with the addition of mouse monoclonal anti-GAPDH (GAPDH-71.1; Sigma-Aldrich) at 1:40,000 dilution which was used as a loading control. Optimum antibody concentration were determined to avoid oversaturation of signal (34, 37, 53, 59, 60). The AlphaEase SA software was used to quantify the density of the protein bands. Only unmodified tiff images were used to quantify band intensity. Sample values were averaged from two quantifications. N value represents the number of animals used. Quantification of protein expression was normalized using GAPDH immunoreactivity and data is presented as a percentage of WT expression. Results are presented as mean ± SEM. Statistical significance was determined with Graphpad Prism 5 by using one-way ANOVA and Tukey’s multiple comparison tests.

Open Field Testing

Testing was conducted on adult age-matched (2-4 months) animals. All mice were naive to the test. The experimenters were blind to the vector treatment at the time of testing. Locomotor
activity testing was performed in an open field locomotor monitor system (Accuscan Images, Salt Lake City). Testing was performed between 13:00 and 17:00 on PND 55 ± 2. Mice were acclimated to the testing room for 5 min, then placed in the open field and monitored for 20 min in low light conditions (~40 lux). The total distance travelled over 20 min was recorded using the Fusion software (Fusion software, Johannesburg, South Africa) and the first 10 minutes compared between groups using one-way ANOVA and Tukey’s multiple comparison tests. Two-way ANOVA excluded sex as a variable, thus male and female homozygous-null mice data from the same groups were combined. The locomotor path plotter function was used to visualize the total exploratory trajectory of individual mice. Results are presented as mean ± SEM.

**Statistical Analyses**

For all parametric data, one-way ANOVA was performed followed by Tukey's post hoc test unless otherwise indicated. Correlation and normality distribution was determined using protein expression as a function of the behavioral data or the cognate protein expression obtained from the same mouse. GraphPad Prism 5 was used to perform the statistical analyses. A $p$ value of $< 0.05$ was deemed statistically significant.

**Acknowledgements**

This work was funded by the Canadian Institutes of Health Research (to JHE, LYW and DRH) and Canada Research Chair Program (to LYW). J.A. and A.H. were recipients of the Fragile X Research Foundation of Canada Post-doctoral Fellowship. The authors thank Dr. Stephanie Anger for the use of the confocal microscope.
Conflict of Interest Statement

The authors declare no competing financial interest.
References

1 Budimirovic, D.B. and Kaufmann, W.E. (2011) What can we learn about autism from studying fragile X syndrome? *Developmental neuroscience, 33*, 379-394.
2 Liyanage, V.R. and Rastegar, M. (2014) Rett syndrome and MeCP2. *Neuromolecular medicine, 16*, 231-264.
3 Lozano, R., Rosero, C.A. and Hagerman, R.J. (2014) Fragile X spectrum disorders. *Intractable & rare diseases research, 3*, 134-146.
4 Loesch, D.Z., Huggins, R.M. and Hagerman, R.J. (2004) Phenotypic variation and FMRP levels in fragile X. *Mental retardation and developmental disabilities research reviews, 10*, 31-41.
5 Guy, J., Gan, J., Selfridge, J., Cobb, S. and Bird, A. (2007) Reversal of neurological defects in a mouse model of Rett syndrome. *Science, 315*, 1143-1147.
6 Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U. and Zoghbi, H.Y. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nature genetics, 23*, 185-188.
7 Abbeduto, L.O., Susan; Thurman, Angela John. (2014) Hales, R.E., Yudofsky, S.C., Roberts, L.W. and American Psychiatric Publishing. (eds.), In *The American Psychiatric Publishing textbook of psychiatry*. American Psychiatric Pub., Washington, DC, in press.
8 Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W. *et al.* (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell, 146*, 247-261.
9 Ascano, M., Jr., Mukherjee, N., Bandaru, P., Miller, J.B., Nusbaum, J.D., Corcoran, D.L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M. *et al.* (2012) FMRP targets distinct mRNA sequence elements to regulate protein expression. *Nature, 492*, 382-386.
10 Tsang, B., Arsenault, J., Vernon, R.M., Lin, H., Sonenberg, N., Wang, L.Y., Bah, A. and Forman-Kay, J.D. (2019) Phosphoregulated FMRP phase separation models activity-dependent translation through bidirectional control of mRNA granule formation. *Proceedings of the National Academy of Sciences of the United States of America, in press.*
11 Jin, P., Alisch, R.S. and Warren, S.T. (2004) RNA and microRNAs in fragile X mental retardation. *Nature cell biology, 6*, 1048-1053.
12 Liu, T., Wan, R.P., Tang, L.J., Liu, S.J., Li, H.J., Zhao, Q.H., Liao, W.P., Sun, X.F., Yi, Y.H. and Long, Y.S. (2015) A MicroRNA Profile in Fmr1 Knockout Mice Reveals MicroRNA Expression Alterations with Possible Roles in Fragile X Syndrome. *Molecular neurobiology, 51*, 1053-1063.
13 Smalheiser, N.R. and Lugli, G. (2009) microRNA regulation of synaptic plasticity. *Neuromolecular medicine, 11*, 133-140.
14 Westmark, C.J. (2013) FMRP: a triple threat to PSD-95. *Frontiers in cellular neuroscience, 7*, 57.
15 Zalfa, F., Eleuteri, B., Dickson, K.S., Mercaldo, V., De Rubeis, S., di Penta, A., Tabolacci, E., Chiurazzi, P., Neri, G., Grant, S.G. *et al.* (2007) A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. *Nature neuroscience, 10*, 578-587.
16 Adinolfi, S., Ramos, A., Martin, S.R., Dal Piaz, F., Pucci, P., Bardonì, B., Mandel, J.L. and Pastore, A. (2003) The N-terminus of the fragile X mental retardation protein contains a novel domain involved in dimerization and RNA binding. *Biochemistry, 42*, 10437-10444.
17 Zhang, Y., Brown, M.R., Hyland, C., Chen, Y., Kronengold, J., Fleming, M.R., Kohn, A.B., Moroz, L.L. and Kaczmarek, L.K. (2012) Regulation of neuronal excitability by interaction of fragile X mental retardation protein with slack potassium channels. *The Journal of neuroscience : the official journal of the Society for Neuroscience, 32*, 15318-15327.
Yang, Y.M., Arsenault, J., Bah, A., Krzeminski, M., Fekete, A., Chao, O.Y., Pacey, L.K., Wang, A., Forman-Kay, J., Hampson, D.R. et al. (2018) Identification of a molecular locus for normalizing dysregulated GABA release from interneurons in the Fragile X brain. Molecular psychiatry, in press.

Khayachi, A., Gwizdek, C., Poupon, G., Alcor, D., Chafai, M., Casse, F., Maurin, T., Prieto, M., Folci, A., De Graeve, F. et al. (2018) Sumoylation regulates FMRP-mediated dendritic spine elimination and maturation. Nature communications, 9, 757.

Chahrour, M., Jung, S.Y., Shaw, C., Zhou, X., Wong, S.T., Qin, J. and Zoghbi, H.Y. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science, 320, 1224-1229.

Sugino, K., Hempel, C.M., Okaty, B.W., Arnsen, H.A., Kato, S., Dani, V.S. and Nelson, S.B. (2014) Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes. The Journal of neuroscience : the official journal of the Society for Neuroscience, 34, 12877-12883.

Li, R., Dong, Q., Yuan, X., Zeng, X., Gao, Y., Chiao, C., Li, H., Zhao, X., Keles, S., Wang, Z. et al. (2016) Misregulation of Alternative Splicing in a Mouse Model of Rett Syndrome. PLoS genetics, 12, e1006129.

Young, J.I., Hong, E.P., Castle, J.C., Crespo-Barreto, J., Bowman, A.B., Rose, M.F., Kang, D., Richman, R., Johnson, J.M., Berget, S. et al. (2005) Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proceedings of the National Academy of Sciences of the United States of America, 102, 17551-17558.

Wu, H., Tao, J., Chen, P.J., Shahab, A., Ge, W., Hart, R.P., Ruan, X., Ruan, Y. and Sun, Y.E. (2010) Genome-wide analysis reveals methyl-CpG-binding protein 2-dependent regulation of microRNAs in a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America, 107, 18161-18166.

Rodrigues, D.C., Kim, D.S., Yang, G., Zaslavsky, K., Ha, K.C., Mok, R.S., Ross, P.J., Zhao, M., Piekna, A., Wei, W. et al. (2016) MECP2 Is Post-transcriptionally Regulated during Human Neurodevelopment by Combinatorial Action of RNA-Binding Proteins and miRNAs. Cell reports, 17, 720-734.

Hickey, S.E., Walters-Sen, L., Mosher, T.M., Pfau, R.B., Pyatt, R., Snyder, P.J., Sotos, J.F. and Prior, T.W. (2013) Duplication of the Xq27.3-q28 region, including the FMR1 gene, in an X-linked hypogonadism, gynecomastia, intellectual disability, short stature, and obesity syndrome. American journal of medical genetics. Part A, 161A, 2294-2299.

Nagamani, S.C., Erez, A., Probst, F.J., Bader, P., Evans, P., Baker, L.A., Fang, P., Bertin, T., Hixson, P., Stankiewicz, P. et al. (2012) Small genomic rearrangements involving FMR1 support the importance of its gene dosage for normal neurocognitive function. Neurogenetics, 13, 333-339.

Rio, M., Malan, V., Boissel, S., Toutain, A., Royer, G., Gobin, S., Morichon-Delvallez, N., Turleau, C., Bonnefont, J.P., Munich, A. et al. (2010) Familial interstitial Xq27.3q28 duplication encompassing the FMR1 gene but not the MECP2 gene causes a new syndromic mental retardation condition. European journal of human genetics : EJHG, 18, 285-290.

Vengoechea, J., Parikh, A.S., Zhang, S. and Tassone, F. (2012) De novo microduplication of the FMR1 gene in a patient with developmental delay, epilepsy and hyperactivity. European journal of human genetics : EJHG, 20, 1197-1200.

Van Esch, H. (2012) MECP2 Duplication Syndrome. Molecular syndromology, 2, 128-136.

Smyk, M., Obersztyn, E., Nowakowska, B., Nawara, M., Cheung, S.W., Mazurczak, T., Stankiewicz, P. and Bocian, E. (2008) Different-sized duplications of Xq28, including MECP2, in three males with mental retardation, absent or delayed speech, and recurrent infections. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 147B, 799-806.

Lombardi, L.M., Baker, S.A. and Zoghbi, H.Y. (2015) MECP2 disorders: from the clinic to mice and back. The Journal of clinical investigation, 125, 2914-2923.
Fieremans, N., Bauters, M., Belet, S., Verbeek, J., Jansen, A.C., Seneca, S., Roelens, F., De Baere, E., Marynen, P. and Froyen, G. (2014) De novo MECP2 duplications in two females with intellectual disability and unfavorable complete skewed X-inactivation. Human genetics, 133, 1359-1367.

Arsenault, J., Ghelizadeh, S., Niibori, Y., Pacey, L.K., Halder, S.K., Koxhioni, E., Konno, A., Hirai, H. and Hampson, D.R. (2016) FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype. Human gene therapy, 27, 982-996.

Olson, C.O., Zachariah, R.M., Ezeonwuka, C.D., Liyanage, V.R. and Rastegar, M. (2014) Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within MeCP2 regulatory elements. PLoS one, 9, e90645.

Ding, Q., Sethna, F. and Wang, H. (2014) Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background. Behavioural brain research, 271, 72-78.

Wither, R.G., Lang, M., Zhang, L. and Eubanks, J.H. (2013) Regional MeCP2 expression levels in the female MeCP2-deficient mouse brain correlate with specific behavioral impairments. Experimental neurology, 239, 49-59.

Jugloff, D.G., Vandamme, K., Logan, R., Visanji, N.P., Brotridge, J.M. and Eubanks, J.H. (2008) Targeted delivery of an MeCP2 transgene to forebrain neurons improves the behavior of female MeCP2-deficient mice. Human molecular genetics, 17, 1386-1396.

Martinez de Paz, A., Khajavi, L., Martin, H., Claveria-Gimen, R., Tom Dieck, S., Cheema, M.S., Sanchez-Mut, J.V., Moksa, M.M., Carles, A., Brodie, N.I. et al. (2019) MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2. Epigenetics & chromatin, 12, 63.

Couvert, P., Bienvenu, T., Aquaviva, C., Poirier, K., Moraine, C., Gendrot, C., Verloes, A., Andres, C., Le Fevre, A.C., Souville, I. et al. (2001) MECP2 is highly mutated in X-linked mental retardation. Human molecular genetics, 10, 941-946.

Tzeng, C.C., Liou, C.P., Li, C.F., Lai, M.C., Tsai, L.P., Cho, W.C. and Chang, H.T. (2009) Methyl-CpG-binding PCR of bloodspots for confirmation of fragile X syndrome in males. Journal of biomedicine & biotechnology, 2009, 643692.

Edbauer, D., Neilson, J.R., Foster, K.A., Wang, C.F., Seeburg, D.P., Batterton, M.N., Tada, T., Dolan, B.M., Sharp, P.A. and Sheng, M. (2010) Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron, 65, 373-384.

Zhou, Y., Hu, Y., Sun, Q. and Xie, N. (2019) Non-coding RNA in Fragile X Syndrome and Converging Mechanisms Shared by Related Disorders. Frontiers in genetics, 10, 139.

Peier, A.M., McIlwain, K.L., Kenneson, A., Warren, S.T., Paylor, R. and Nelson, D.L. (2000) (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Human molecular genetics, 9, 1145-1159.

Bodda, C., Tantra, M., Mollajew, R., Arunchalam, J.P., Laccone, F.A., Can, K., Rosenberger, A., Mironov, S.L., Ehrenreich, H. and Mannan, A.U. (2013) Mild overexpression of Mecp2 in mice causes a higher susceptibility toward seizures. The American journal of pathology, 183, 195-210.

Collins, A.L., Levenson, J.M., Vilaythong, A.P., Richman, R., Armstrong, D.L., Noebels, J.L., David Sweatt, J. and Zoghbi, H.Y. (2004) Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Human molecular genetics, 13, 2679-2689.
49 Retico, A., Giuliano, A., Tancredi, R., Cosenza, A., Apicella, F., Narzisi, A., Biagi, L., Tosetti, M., Muratori, F. and Calderoni, S. (2016) The effect of gender on the neuroanatomy of children with autism spectrum disorders: a support vector machine case-control study. *Molecular autism, 7*, 5.

50 Mottron, L., Duret, P., Mueller, S., Moore, R.D., Forget d’Arc, B., Jacquemont, S. and Xiong, L. (2015) Sex differences in brain plasticity: a new hypothesis for sex ratio bias in autism. *Molecular autism, 6*, 33.

51 Guy, J., Hendrich, B., Holmes, M., Martin, J.E. and Bird, A. (2001) A mouse MeCP2-null mutation causes neurological symptoms that mimic Rett syndrome. *Nature genetics, 27*, 322-326.

52 Gholizadeh, S., Tharmalingam, S., Macaldaz, M.E. and Hampson, D.R. (2013) Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. *Human gene therapy methods, 24*, 205-213.

53 Pacey, L.K., Doss, L., Cifelli, C., van der Kooy, D., Heximer, S.P. and Hampson, D.R. (2011) Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. *Molecular and cellular neurosciences, 46*, 563-572.

54 Arsenault, J., Ferrari, E., Niranjan, D., Cuijpers, S.A., Gu, C., Vallis, Y., O’Brien, J. and Davletov, B. (2013) Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells. *Journal of neurochemistry, 126*, 223-233.

55 Gholizadeh, S., Halder, S.K. and Hampson, D.R. (2015) Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain. *Brain research, 1596*, 22-30.

56 Gabel, L.A., Won, S., Kawai, H., McKinney, M., Tartakoff, A.M. and Fallon, J.R. (2004) Visual experience regulates transient expression and dendritic localization of fragile X mental retardation protein. *The Journal of neuroscience : the official journal of the Society for Neuroscience, 24*, 10579-10583.

57 LaFauci, G., Adayev, T., Kascsak, R., Kascsak, R., Nolin, S., Mehta, P., Brown, W.T. and Dobkin, C. (2013) Fragile X screening by quantification of FMRP in dried blood spots by a Luminex immunoassay. *The Journal of molecular diagnostics : JMD, 15*, 508-517.

58 Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A.F., Boguski, M.S., Brockway, K.S., Byrnes, E.J. et al. (2007) Genome-wide atlas of gene expression in the adult mouse brain. *Nature, 445*, 168-176.

59 Pacey, L.K., Xuan, I.C., Guan, S., Sussman, D., Henkelman, R.M., Chen, Y., Thomsen, C. and Hampson, D.R. (2013) Delayed myelination in a mouse model of fragile X syndrome. *Human molecular genetics, 22*, 3920-3930.

60 Pacey, L.K., Guan, S., Tharmalingam, S., Thomsen, C. and Hampson, D.R. (2015) Persistent astrocyte activation in the fragile X mouse cerebellum. *Brain and behavior, 5*, e00400.
Legends to Figures

Figure 1. MeCP2 transcript analysis and cellular co-distribution of MeCP2 and FMRP in the wild-type mouse brain. (A-C) Photomicrographs of the cerebral cortex (A), striatum (B), and hippocampus (C) showing co-localization of MeCP2 and FMRP. (D-F) Photo-micrographs of the deep cerebellar nuclei (DCN) under low (D) and high magnification (E). (F) Example of cerebellar cortex showing the Purkinje neuron layer situated between the molecular layer (right) and granule cell layer (left). Anti-FMRP is shown in green and anti-MeCP2 is shown in red. White bar = 20μm. CB: cerebellum; DCN: deep cerebellar nuclei. Reverse transcription of mRNA from wild-type mouse. (G) PSD-95 mRNA reverse transcribed from total mouse brain mRNA, supernatant (input), non-specific IgG pull-down, and anti-FMRP pull-down was used as a positive control. (H) MeCP2 transcript variant 1 reverse transcribed mRNA, and (I) MeCP2 transcript variant 2 reverse transcribed mRNA screening. N = 4 mice for all conditions. Input: total isolated mRNA; P.D.: pull-down; M.B.: mouse brain total mRNA; bp: base pairs; t.v.: transcript variant; E.S.: expected size of band.
Figure 2. Expression of FMRP and MeCP2 in wild-type and AAV-FMRP transduced Fmr1 KO mouse brain and individual neurons. (A) Q-RT-PCR of MeCP2 mRNA in WT and Fmr1 KO mouse forebrain. GAPDH mRNA was used to normalize quantification and the results are presented as relative mRNA expression (arbitrary units; mean ± SEM). (B) Western blot of MeCP2 in the cerebral cortex of WT + EV, KO + EV, and KO mice transduced with AAV-FMRP. (C) Densitometric quantification of MeCP2 protein expression from western blots of the cortices of WT + EV, KO + EV, and KO + AAV-FMRP treated mice. GAPDH was used to normalize protein amounts; results are presented as a percentage of WT expression (mean ± SEM). The numbers of replicates (mice) are indicated within the bars (*p < 0.05, **p < 0.01). (D) Scatter plot of quantified FMRP and MeCP2 cellular immunoreactive intensities from 3 serial coronal slides obtained from 4 different Fmr1 KO mice injected with AAV-FMRP.
MeCP2 and FMRP display an inverse relationship where high expression (arbitrary cutoff) of MeCP2 correlates with low FMRP expression and vice versa. Only 1% of cells exists in the high-FMRP and high-MeCP2 quadrant (top right), indicating that cells under elevated translational modulation (high-FMRP; 7%) generally does not occur in the same cells as those under elevated transcriptional modulation (high-MeCP2; 19%). To assure a proper plane of focus on the nucleus, DAPI staining was used to select cells. R.F.U.: Relative Fluorescence Units. (E) Example photomicrograph of the sensorimotor cortex from a 2-month old Fmr1 KO mouse transduced with AAV-FMRP labeled with anti-FMRP (green) and anti-MeCP2 (red) immunostaining. Nuclei were counterstained with DAPI (blue). Merged image shows the composite overlay. White bar = 50 μm.
Figure 3. FMRP and MeCP2 protein expression in MeCP2 KO mice. (A) Western blots of MeCP2 in WT and MeCP2 KO mouse cerebellum. (B-C) FMRP expression in WT and MeCP2 KO mouse cerebellum (B) and sensorimotor cortex (C). (D-E) Densitometric quantification of FMRP expression in MeCP2 KO mice from the cerebellum (panel D; 86 ±5%, p = 0.1364) and sensorimotor cortex (panel E; 78 ±5%; p < 0.01) of WT expression. Expression was normalized to GAPDH. Numbers inside columns indicate the number of mice analyzed in each group. Data are presented as a percentage of WT expression (mean ± SEM). **p < 0.01.
Figure 4. Assay of different shRNA targeting the MeCP2 transcript. (A) Western immunoblot of MeCP2, FMRP, and GAPDH from Neuroblastoma cells transfected with commercially available shRNAs (Full clone IDs are available in methods section). (B) Quantification of MeCP2 expression following shRNA transfection. All commercial shRNAs were able to significantly reduce MeCP2 expression compared to no shRNA transfection (NT) control (p<0.05). (C) Quantification of FMRP following MeCP2 shRNA transfection. shRNA clones 579, 1266, and 1266s21 showed consistent downregulation of FMRP following MeCP2 knockdown.
**Figure 5. Manipulating MeCP2 protein expression in human embryonic kidney cells using AAV MeCP2 shRNA.** (A) Immunoblots of MeCP2, GFP, FMRP and GAPDH in HEK-293 cells following increasing titers of AAV MeCP2 shRNA. (B) Dose effect curve of AAV MeCP2 shRNA on MeCP2, GFP, and FMRP expression. (C) Quantification of MeCP2 knockdown with increasing doses of AAV MeCP2 shRNA. Significant knockdown was observed at the $6 \times 10^7$ GC/ml titer ($p < 0.05$). (D) Quantification of FMRP expression following MeCP2 knockdown. A significant reduction in FMRP expression was observed following a $2 \times 10^7$ GC/ml titer administration ($p < 0.05$) and at the higher titer ($p < 0.01$). Expression was normalized to GAPDH and control cell (no AAV) expression was set at 100%. Results are presented as mean ± SEM obtained from three independent experiments.
Figure 6. Locomotor activity and brain MeCP2 expression in AAV-transduced wild-type and Fmr1 KO mice. (A) Locomotor path plotter for typical WT + EV, KO + EV, and KO + AAV-FMRP treated mice. Rainbow gradient shows the start (blue) to end of trial (red). (B) Total distance travelled within the first 10 minutes shows significant locomotor hyperactivity in the Fmr1 KO mice injected with the AAV control null vector (*p < 0.05). (C) Scatter plot distribution of the total distance travelled and FMRP expression in the cortex of individual mice. (D) Correlation between the total distance travelled and the MeCP2 expression in individual mice; MeCP2 protein expression significantly correlated (p < 0.01) with the severity of the locomotor hyperactivity phenotype. (E) Correlation between the expression of MeCP2 in individual mice from the PBS-injected WT and Fmr1 KO + AAV-FMRP groups and total distance travelled (previously unpublished analysis) from our previous study (37).
Introductory Figure

Interregulation between MeCP2 and FMRP. MeCP2, a transcriptional modulator, contributes to the upregulation of FMRP expression. FMRP, a translational modulator, contributes to the downregulation of MeCP2 translation. MeCP2 KO mice are hypoactive. Fmr1 KO mice display hyperactivity.
Abbreviations

FMRP, Fragile X Mental Retardation Protein; MeCP2, Methyl CpG binding protein 2; FXS, Fragile X Syndrome; AAV, Adeno-associated Virus; ASD, Autism Spectrum Disorders; EV, Empty Vector; PSD-95, Postsynaptic density protein 95; shRNA, short hairpin RNA; HEK, Human Embryonic Kidney; N2A, Neuroblastoma 2A.